{"id":131,"date":"2024-08-09T22:00:00","date_gmt":"2024-08-09T22:00:00","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=131"},"modified":"2025-11-13T09:41:34","modified_gmt":"2025-11-13T09:41:34","slug":"china-bd-2024-curon-and-msd-enters-a-1-3-billion-usd-transaction-for-cd3xcd19-targeting-tce-biabs-cn201","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2024\/131.html","title":{"rendered":"[China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201\u00a0"},"content":{"rendered":"\n<p>Announced Date: 2024-08-07 (August 7, 2024)<\/p>\n\n\n\n<p>Asset Name: CN201&nbsp;<\/p>\n\n\n\n<p>Licensor: Curon (Curon Biopharmaceutical&nbsp;, China)<\/p>\n\n\n\n<p>Licensee (Buyer): MSD \uff08Merck &amp; Co., Inc\uff0cUSA\uff09<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Modality: T-cell-engager bispecific antibody<\/p>\n\n\n\n<p>Asset Target: CD3xCD19-targeting<\/p>\n\n\n\n<p>&nbsp;Potential Indication: B-cell associated diseases<\/p>\n\n\n\n<p>Current Stage: Phase 1 and Phase 1b\/2 clinical trials<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority:<\/p>\n\n\n\n<p>MSD through a subsidiary will acquire full global rights to CN201.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Deal Detail:<\/p>\n\n\n\n<p>Upfront payment of&nbsp;$700 million,<\/p>\n\n\n\n<p>Development and regulatory milestone payments up to &nbsp;$600 million,<\/p>\n\n\n\n<p>Total up to 1.3 billion.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/www.msd.com\/news\/msd-to-acquire-investigational-b-cell-depletion-therapy-cn201-from-curon-biopharmaceutical\/\">MSD to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical &#8211; MSD<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Curon Biopharmaceutical\u00a0 \u540c\u6da6\u751f\u7269<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2024-08-07 (August 7, 2024) Asset Name: CN201&nbsp; Licensor: Curon (Curon Biopharmaceutical&nbsp;, China) Licensee (Buyer): &hellip; <a title=\"[China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201\u00a0\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2024\/131.html\"><span class=\"screen-reader-text\">[China BD 2024] Curon and MSD enters a 1.3 billion USD transaction for CD3xCD19-targeting TCE BiAbs CN201\u00a0<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-131","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=131"}],"version-history":[{"count":2,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/131\/revisions"}],"predecessor-version":[{"id":420,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/131\/revisions\/420"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}